JP2006500002A5 - - Google Patents

Download PDF

Info

Publication number
JP2006500002A5
JP2006500002A5 JP2003548687A JP2003548687A JP2006500002A5 JP 2006500002 A5 JP2006500002 A5 JP 2006500002A5 JP 2003548687 A JP2003548687 A JP 2003548687A JP 2003548687 A JP2003548687 A JP 2003548687A JP 2006500002 A5 JP2006500002 A5 JP 2006500002A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
level
individual
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003548687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006500002A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/038556 external-priority patent/WO2003047421A2/en
Publication of JP2006500002A publication Critical patent/JP2006500002A/ja
Publication of JP2006500002A5 publication Critical patent/JP2006500002A5/ja
Pending legal-status Critical Current

Links

JP2003548687A 2001-12-03 2002-12-02 糖尿病の診断および治療のための方法および試薬 Pending JP2006500002A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33663301P 2001-12-03 2001-12-03
PCT/US2002/038556 WO2003047421A2 (en) 2001-12-03 2002-12-02 Methods and reagents for diagnosis and treatment of diabetes

Publications (2)

Publication Number Publication Date
JP2006500002A JP2006500002A (ja) 2006-01-05
JP2006500002A5 true JP2006500002A5 (enExample) 2006-02-16

Family

ID=23316971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003548687A Pending JP2006500002A (ja) 2001-12-03 2002-12-02 糖尿病の診断および治療のための方法および試薬

Country Status (6)

Country Link
US (2) US7144985B2 (enExample)
EP (1) EP1461351A4 (enExample)
JP (1) JP2006500002A (enExample)
AU (1) AU2002351214B2 (enExample)
CA (1) CA2468991A1 (enExample)
WO (1) WO2003047421A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7054758B2 (en) 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
AU2002306853B2 (en) * 2001-03-15 2006-07-06 Research Development Foundation Urocortin-III and uses thereof
WO2009045370A2 (en) 2007-09-28 2009-04-09 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
CA2742710A1 (en) * 2008-11-04 2010-05-14 Janssen Pharmaceutica Nv Crhr2 peptide agonists and uses thereof
EP2584041A1 (en) * 2011-10-21 2013-04-24 Industrial Cooperation Foundation Chonbuk National University Composition for preventing or treating diabetes comprising nad glycohydrolase inhibitor as active ingredient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
AU2002306853B2 (en) 2001-03-15 2006-07-06 Research Development Foundation Urocortin-III and uses thereof

Similar Documents

Publication Publication Date Title
Lund et al. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem.
Huizing et al. Cloning of the human carnitine-acylcarnitine carrier cDNA and identification of the molecular defect in a patient
Otsuka et al. Identification of essential amino acid residues of the NorM Na+/multidrug antiporter in Vibrio parahaemolyticus
EP2629797B1 (en) Peptides for modulating t-cell activity and uses thereof
DE777732T1 (de) Modulatoren von dem körpergewicht, entsprechende nukleinsaüre und proteine, und diagnostische und therapeutische anwendungen davon
Kissel et al. Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin
CA2336218A1 (en) Neurotrophic factors
JP2005535290A5 (enExample)
WO2004076639B1 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
JPH04503808A (ja) 新規インシュリン化合物
JP2006502702A5 (enExample)
Wei et al. Quantitative candidate gene association studies of metabolic traits in Han Chinese type 2 diabetes patients
WO2018129421A1 (en) A promising drug candidate for parkinson's disease
JP2006500002A5 (enExample)
Wang et al. Distinct domains of IFNα mediate immune and analgesic effects respectively
JP2002515223A5 (enExample)
JP2005528921A5 (enExample)
JP2009516155A5 (enExample)
JP2005529603A5 (enExample)
Li et al. Mutations in GCK may lead to MODY2 by reducing glycogen synthesis
CN1962695B (zh) 类胰高血素肽-1融合蛋白及其制备和用途
CN101220089A (zh) 中国南海信号芋螺神经毒素基因Lt3.1及其应用
CN1287124A (zh) 重组天然和新型人胰岛素及其制备方法
EP2032601B1 (en) Peptides regulating the surface expression of the t cell receptor
JP2004533841A5 (enExample)